<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Enzyme Inhib Med Chem</span><span class="iso-abbrev" title="iso-abbrev">J Enzyme Inhib Med Chem</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Enzyme Inhibition and Medicinal Chemistry</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1475-6366</span><span class="issn-epub" tagx="issn" title="issn-epub">1475-6374</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Taylor &amp;amp; Francis</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7808749">7808749</a></span><span class="pmid" title="pmid"> pmid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/33430657">33430657</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1080/14756366.2020.1842390">10.1080/14756366.2020.1842390</a></span><span class="publisher-id" title="publisher-id">1842390</span><div class="unknown" title="article-version" tag="article-version">
Version of Record</div> <div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research Article</span>: <span class="subject" title="subject">Short Communication</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Morpholine-based chalcones as dual-acting monoamine oxidase-B and acetylcholinesterase inhibitors: synthesis and biochemical investigations</div> <div class="alt-title" title="alt-title">
R. Sasidharan et al.</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sasidharan</span><span class="given-names" tagx="given-names" title="given-names">Rani</span></span><a href="#AF0001">a</a><a href="#AF0002">b</a><a href="#FN0002" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eom</span><span class="given-names" tagx="given-names" title="given-names">Bo Hyun</span></span><a href="#AF0003">c</a><a href="#FN0002" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Heo</span><span class="given-names" tagx="given-names" title="given-names">Jeong Hyun</span></span><a href="#AF0003">c</a><a href="#FN0002" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">Jong Eun</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdelgawad</span><span class="given-names" tagx="given-names" title="given-names">Mohamed A.</span></span><a href="#AF0004">d</a><a href="#AF0005">e</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Musa</span><span class="given-names" tagx="given-names" title="given-names">Arafa</span></span><a href="#AF0006">f</a><a href="#AF0007">g</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gambacorta</span><span class="given-names" tagx="given-names" title="given-names">Nicola</span></span><a href="#AF0008">h</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nicolotti</span><span class="given-names" tagx="given-names" title="given-names">Orazio</span></span><a href="#AF0008">h</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Manju</span><span class="given-names" tagx="given-names" title="given-names">Sreedharannair Leelabaiamma</span></span><a href="#AF0002">b</a><a href="#AN0003" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">Bijo</span></span><a href="#AF0009">i</a><a href="#AN0002" /><a href="#FN0001" /></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0002-7203-3712</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">Hoon</span></span><a href="#AF0003">c</a><a href="#AN0001" /></span><span class="citation_author_institution" id="AF0001">[a], <span class="institution" title="institution">College of Pharmaceutical Science, Government T.D. Medical College</span><span class="city" tagx="city" title="city">Alappuzha</span><span class="country" tagx="country" title="country">India</span></span><span class="citation_author_institution" id="AF0002">[b], <span class="institution" title="institution">Organic Chemistry Division, SAS, VIT University</span><span class="city" tagx="city" title="city">Vellore</span><span class="country" tagx="country" title="country">India</span></span><span class="citation_author_institution" id="AF0003">[c], <span class="institution" title="institution">Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University</span><span class="city" tagx="city" title="city">Suncheon</span><span class="country" tagx="country" title="country">Republic of Korea</span></span><span class="citation_author_institution" id="AF0004">[d], <span class="institution" title="institution">Pharmaceutical Chemistry Department, College of Pharmacy, Jouf University</span><span class="city" tagx="city" title="city">Sakaka</span><span class="country" tagx="country" title="country">Saudi Arabia</span></span><span class="citation_author_institution" id="AF0005">[e], <span class="institution" title="institution">Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University</span><span class="city" tagx="city" title="city">Beni Suef</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0006">[f], <span class="institution" title="institution">Department of Pharmacogonosy, College of Pharmacy, Jouf University</span><span class="city" tagx="city" title="city">Sakaka</span><span class="country" tagx="country" title="country">Saudi Arabia</span></span><span class="citation_author_institution" id="AF0007">[g], <span class="institution" title="institution">Department of Pharmacogonosy, Al-Azhar University</span><span class="city" tagx="city" title="city">Cairo</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0008">[h], <span class="institution" title="institution">Dipartimento di Farmaciaâ€"Scienze del Farmaco, UniversitÃ degli Studi di Bari â€œAldo Moroâ€�</span><span class="city" tagx="city" title="city">Bari</span><span class="country" tagx="country" title="country">Italy</span></span><span class="citation_author_institution" id="AF0009">[i], <span class="institution" title="institution">Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy</span><span class="city" tagx="city" title="city">Palakkad</span><span class="country" tagx="country" title="country">India</span></span></div> <div class="author-notes" title="author-notes"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>#</sup></span><p>These authors contributed equally to this work.</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label">*</span><p>Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682 041, India.</p> </div> <div class="fn-type-" title=""> <p content-type="appended text">Supplemental data for this article can be accessed <a href="https://doi.org/10.1080/14756366.2020.1842390"><u>here</u></a>.</p> </div> <div class="corresp" title="corresp">
CONTACT Hoon Kim <span class="email" tagx="email" title="email">hoon@sunchon.ac.kr</span><span class="institution" title="institution">Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University</span>, <span class="city" tagx="city" title="city">Suncheon</span><span class="postal-code" tagx="postal-code" title="postal-code">57922</span>, <span class="country" tagx="country" title="country">Republic of Korea</span></div> <div class="corresp" title="corresp">
Bijo Mathew <span class="email" tagx="email" title="email">bijomathew@aims.amrita.edu</span>Â Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682 041, India</div> <div class="corresp" title="corresp">
Sreedharannair Leelabaiamma Manju <span class="email" tagx="email" title="email">slmanju@vit.ac.in</span><span class="institution" title="institution">Organic Chemistry Division, SAS, VIT University</span>, <span class="city" tagx="city" title="city">Vellore</span>, <span class="country" tagx="country" title="country">India</span></div> </div><span class="pub-date-" title="pub-date-">: <span>2021-1-1</span></span><span class="pub-date-" title="pub-date-">: <span>2021</span></span><span class="volume" tagx="volume" title="volume">36</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">188</span><span class="lpage" tagx="lpage" title="lpage">197</span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">The Author(s)</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2021</span></span><span class="license" title="license"><span class="license-p" title="license-p">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</span></span></div><a class="self-uri" href="IENZ_36_1842390.pdf" title="self-uri">IENZ_36_1842390.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>Nine compounds (<b>MO1â€"MO9</b>) containing the morpholine moiety were assessed for their inhibitory activities against monoamine oxidases (MAOs) and acetylcholinesterase (AChE). Most of the compounds potently inhibited MAO-B; <b>MO1</b> most potently inhibited with an IC<sub>50</sub> value of 0.030â€‰ÂµM, followed by <b>MO7</b> (0.25â€‰ÂµM). <b>MO5</b> most potently inhibited AChE (IC<sub>50</sub> = 6.1â€‰ÂµM), followed by <b>MO9</b> (IC<sub>50</sub> = 12.01â€‰ÂµM) and <b>MO7</b> most potently inhibited MAO-A (IC<sub>50</sub> = 7.1â€‰ÂµM). <b>MO1</b> was a reversible mixed-type inhibitor of MAO-B (<i>K<sub>i</sub></i> = 0.018â€‰ÂµM); <b>MO5</b> reversibly competitively inhibited AChE (<i>K<sub>i</sub></i> = 2.52â€‰ÂµM); and <b>MO9</b> reversibly noncompetitively inhibited AChE (<i>K<sub>i</sub></i> = 7.04â€‰ÂµM). <b>MO1</b>, <b>MO5</b> and <b>MO9</b> crossed the bloodâ€"brain barrier, and were non-toxic to normal VERO cells. These results show that <b>MO1</b> is a selective inhibitor of MAO-B and that <b>MO5</b> is a dual-acting inhibitor of AChE and MAO-B, and that both should be considered candidates for the treatment of Alzheimerâ€™s disease.</p> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Morpholine-containing chalcone</div> <div class="kwd" title="kwd">
monoamine oxidase</div> <div class="kwd" title="kwd">
acetylcholinesterase</div> <div class="kwd" title="kwd">
dual-acting inhibitor</div> <div class="kwd" title="kwd">
Docking analysis</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1.</span><div class="title" tagx="title" title="title">
Introduction</div> <p>Due to the extreme complexities of brain systems and their diverse dysfunctions, research focus is being directed towards the design of multi-target directed ligands (MTDLs)<a href="#CIT0001"><sup>1</sup></a>. In fact, it has been suggested that functional equilibrium of brain after a neurologic disorder is unlikely to be achieved by focussing on a single molecular target<a href="#CIT0002"><sup>2</sup></a>. The major challenge presented by the development of MTDLs is to preserve balance between the effects drugs have by acting at their individual molecular targets<a href="#CIT0003"><sup>3</sup></a>. On the other hand, some ligands can target two or more specific entities within numerous biological networks. The likelihood of successful MTDL design can be enhanced by considering the design of molecular scaffolds via suitable molecular hybridisation and by understanding the pathophysiologies of multifaceted diseases. The design process can be accelerated by selecting pharmacophores based on pre-clinical studies, emphasising structureâ€"activity relationships (SARs) and by performing <i>in silico</i>-based virtual screening<a href="#CIT0004"><sup>4</sup></a>.</p> <p>Monoamine oxidases (MAOs) play prominent roles in the inactivations of various biogenic amines in central and peripheral tissues. The isoenzymes of MAO-A and MAO-B are considered major therapeutic targets in various neuropsychiatric illnesses and neurodegenerative disorders like Alzheimerâ€™s disease (AD) and Parkinsonâ€™s disease (PD)<a href="#CIT0005"><sup>5</sup></a>. During the degradations of various biogenic neurotransmitters catalysed by MAO-A and MAO-B, hydrogen peroxide and reactive oxygen species (ROS) are produced as major by-products, which might cause oxidative damage in brain tissues. MAO inhibitors are considered potential neuroprotective agents and up-regulating agents for neurotransmitter amines<a href="#CIT0006"><sup>6</sup></a>. Numerous studies have documented that selective and reversible/irreversible MAO-B inhibitors are likely to play pivotal roles in AD-related therapeutic strategies. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors also play significant roles in the maintenance of cholinergic functions and are used to provide symptomatic relief in AD. Over the past two decades, many researchers have tried to develop multi-acting MAO-B and AChE/BChE inhibitors<a href="#CIT0007"><sup>7â€"10</sup></a>.</p> <p>Morpholine is a tetrahydro-1,4-oxazine with a saturated heterocyclic ring and provides a promising developmental starting point due to its biological profile with metabolic stability. The presence of a heteroatom like oxygen or nitrogen facilitates hydrogen bonding, and thus, interactions with enzymes, and the presence of electron-deficient atoms may also impart hydrophobic interactions with morpholine. From the synthetic perspective, various molecular scaffolds have been added to morpholine by replacing its secondary nitrogen<a href="#CIT0011"><sup>11</sup></a>. Moclobemide (1) and reboxetine (2) (both antidepressants) provide examples of FDA-approved drugs containing the morpholine moiety (<a href="#F0001">Figure 1</a>). These drugs reversibly inhibit MAO-A and selectively inhibit norepinephrine reuptake in the central nervous system (CNS), and thus, block the human a4b2 nicotinic acetylcholine receptor. In addition, more than 20 drugs containing the morpholine moiety have been FDA approved; they include mycophenolate mofetil (an immunosuppressant), linezolid and finafloxacin (antibiotics), geftinib (an antineoplastic and epidermal growth factor inhibitor), rivaroxaban (an anticoagulant and factor Xa inhibitor), and eteplirsen, which is used to treat Duchenne muscular dystrophy<a href="#CIT0012"><sup>12</sup></a>. Considering the importance of morpholine nucleus, it is worthwhile to design morpholine derived compounds of medicinal chemistry interest.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1.</span></a></div>   <p>Morpholine-containing, CNS active, FDA approved drugs. 1, moclobemide; 2, reboxetine.</p>   </div> <p>The chalcones framework is considered an excellent starting point for the design for MAO-B and AChE enzyme inhibitors<a href="#CIT0013"><sup>13â€"15</sup></a>. The presence of an Î±-Î² unsaturated ketone and three rotatable bonds in chalcones can provide different bonding orientations<a href="#CIT0016"><sup>16</sup></a>. The literature amply demonstrates that most chalcones are potent, reversible and selective MAO-B inhibitors<a href="#CIT0017"><sup>17</sup></a>. In addition, the presence and orientation of various electron-donating and withdrawing groups on the phenyl/heteroaryl <b>A</b> and <b>B</b> rings of chalcones can impart electrophilic character to the Michael acceptor present. The introductions of electron-donating/lipophilic halogens onto the phenyl <b>B</b> ring of chalcones have resulted in the syntheses of highly selective MAO-B inhibitors<a href="#CIT0018"><sup>18â€"27</sup></a>. Many studies have reported that the presence of various alkylamino groups on the <b>A</b> ring provides AChE inhibitory activity<a href="#CIT0028"><sup>28â€"31</sup></a>. The FDA-approved drugs like flurbiprofen and rivastigmine linked with chalcone moiety were developed as selective ChE/MAO-B inhibitors for the prophylactic agents for AD<a href="#CIT0032"><sup>32</sup></a>. The design strategy of the current study is depicted in <a href="#F0002">Figure 2</a> and the synthetic route is shown in <a href="#s0001">Scheme 1</a>. A recent study showed that the presence of a pendant morpholine ring on the chalcone <b>A</b> ring favoured hMAO-B inhibitory activity<a href="#CIT0033"><sup>33</sup></a><sup>,</sup><a href="#CIT0034"><sup>34</sup></a>. The difference in MAO-B inhibition profiles became more obvious when chalcone <b>B</b> ring was substituted using a fluoro or trifluoromethyl group<a href="#CIT0033"><sup>33</sup></a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 1.</span></a></div>   <p>The synthetic route used to produce the target compounds (<b>MO1â€"MO9</b>).</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 2.</span></a></div>   <p>MTDL design of MAO-B and AChE inhibitors.</p>   </div> </div> <div class="resultsanddiscussion" title="sec"><span class="label" tagx="label" title="label">2.</span><div class="title" tagx="title" title="title">
Results and discussion</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">2.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <p>Morpholine-containing Î±,Î²-unsaturated ketones were prepared by condensation between various aromatic/<i>para</i> substituted aldehydes and 4-morpholine acetophenone in the presence of an alcoholic basic medium<a href="#CIT0033"><sup>33</sup></a>. The H<sup>1</sup> NMR showed that the ring protons N-CH<sub>2</sub> and O-CH<sub>2</sub> of morpholine ring resonated at 3.32â€"3.31 and 3.75â€"3.88â€‰ppm as triplets, respectively. The large coupling constant (<i>Jâ€‰=</i>â€‰15â€‰Hz) value of HÎ± and HÎ² protons confirmed the <i>trans</i> configuration of the morpholine chalcones. The deshielded values between 186.88â€"186.07 in C<sup>13</sup>-NMR clearly evidenced the formation of sp<sup>2</sup> carbonyl functional group of Î±,Î²-unsaturated ketones. The identities of the compounds were determined by <sup>1</sup>H-NMR, <sup>13â€‰</sup>C-NMR and Mass spectrometry (<a href="https://doi.org/10.1080/14756366.2020.1842390">Supplementary materials</a>).</p> </div> <div class="analysisofenzymeinhibitoryactivities" title="sec"><span class="label" tagx="label" title="label">2.2.</span><div class="title" tagx="title" title="title">
Analysis of enzyme inhibitory activities</div> <div class="inhibitoryactivities" title="sec"><span class="label" tagx="label" title="label">2.2.1.</span><div class="title" tagx="title" title="title">
Inhibitory activities</div> <p>In this study, nine morpholine-based compounds (<b>MO1</b>â€"<b>MO9</b>) were analysed with respect to their abilities to inhibit MAO-A, MAO-B and AChE. Most of the compounds inhibited MAO-B by âˆ¼ 50% at 1.0â€‰ÂµM, except <b>MO3</b> and <b>MO5</b> (<a href="#t0001">Table 1</a>). Compound <b>MO1</b> most potently inhibited MAO-B (IC<sub>50</sub> = 0.030â€‰ÂµM), followed by <b>MO7</b>, <b>MO8</b>, <b>MO4</b>, <b>MO9</b>, <b>MO6</b>, <b>MO2</b>, <b>MO3</b> and <b>MO5</b> (IC<sub>50</sub> = 0.25, 0.32, 0.33, 0.36, 0.64, 0.70, 1.01 and 1.31â€‰ÂµM, respectively). In addition, <b>MO5</b> most potently inhibited AChE (IC<sub>50</sub> = 6.1â€‰ÂµM), followed by <b>MO9</b> and <b>MO8</b> (IC<sub>50</sub> = 12.01 and 12.07â€‰ÂµM, respectively). <b>MO7</b> most potently inhibited MAO-A (IC<sub>50</sub> = 7.1â€‰ÂµM), followed by <b>MO6</b> (IC<sub>50</sub> = 8.7â€‰ÂµM). <b>MO5</b> most potently inhibited BChE (IC<sub>50</sub> = 18.09â€‰ÂµM), with weaker inhibitory activity compared to AChE, followed by <b>MO7</b> (IC<sub>50</sub> = 24.83â€‰ÂµM) (<a href="#t0001">Table 1</a>).</p> <div class="table-wrap_UNKNOWN" id="t0001" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1.</span> <p>Inhibitions of MAO-A, MAO-B, and AChE by <b>MO1â€"MO9</b><sup>a</sup></p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Compounds</th> <th colspan="4" align="center">Residual activities (%) <hr /> </th> <th colspan="4" align="center">IC<sub>50</sub> (ÂµM) <hr /> </th> <th rowspan="2" align="center">SI<sup>b</sup></th> </tr> <tr> <th align="center">MAO-A (10 ÂµM)</th> <th align="center">MAO-B (1.0 ÂµM)</th> <th align="center">AChE (10 ÂµM)</th> <th align="center">BChE (10 ÂµM)</th> <th align="center">MAO-A</th> <th align="center">MAO-B</th> <th align="center">AChE</th> <th align="center">BChE</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>MO1</b></td> <td align="char" char="Â±">94.2â€‰Â±â€‰0.62</td> <td align="char" char="Â±">38.1â€‰Â±â€‰9.50</td> <td align="char" char="Â±">53.4â€‰Â±â€‰0.99</td> <td align="char" char="Â±">62.85â€‰Â±â€‰2.97</td> <td align="center">&amp;gt;40</td> <td align="char" char="Â±">0.030â€‰Â±â€‰0.062</td> <td align="char" char="Â±">16.1â€‰Â±â€‰2.24</td> <td align="center">&amp;gt;40</td> <td align="char" char=".">&amp;gt;1333.3</td> </tr> <tr> <td align="left"><b>MO2</b></td> <td align="char" char="Â±">93.8â€‰Â±â€‰1.34</td> <td align="char" char="Â±">54.5â€‰Â±â€‰5.28</td> <td align="char" char="Â±">72.3â€‰Â±â€‰1.34</td> <td align="char" char="Â±">63.55â€‰Â±â€‰3.30</td> <td align="center">&amp;gt;40</td> <td align="char" char="Â±">0.70â€‰Â±â€‰0.23</td> <td align="char" char="Â±">30.2â€‰Â±â€‰3.24</td> <td align="center">&amp;gt;40</td> <td align="char" char=".">&amp;gt; 57.1</td> </tr> <tr> <td align="left"><b>MO3</b></td> <td align="char" char="Â±">91.0â€‰Â±â€‰3.17</td> <td align="char" char="Â±">79.9â€‰Â±â€‰5.28</td> <td align="char" char="Â±">79.3â€‰Â±â€‰2.82</td> <td align="char" char="Â±">56.78â€‰Â±â€‰2.97</td> <td align="center">&amp;gt;40</td> <td align="char" char="Â±">1.01â€‰Â±â€‰0.08</td> <td align="center">&amp;gt;40</td> <td align="center">&amp;gt;40</td> <td align="char" char=".">&amp;gt;39.6</td> </tr> <tr> <td align="left"><b>MO4</b></td> <td align="char" char="Â±">70.2â€‰Â±â€‰1.24</td> <td align="char" char="Â±">49.0â€‰Â±â€‰1.45</td> <td align="char" char="Â±">66.0â€‰Â±â€‰8.79</td> <td align="char" char="Â±">80.30â€‰Â±â€‰6.43</td> <td align="center">25.8â€‰Â±â€‰1.58</td> <td align="char" char="Â±">0.33â€‰Â±â€‰0.03</td> <td align="char" char="Â±">28.42â€‰Â±â€‰0.02</td> <td align="center">&amp;gt;40</td> <td align="char" char=".">78.2</td> </tr> <tr> <td align="left"><b>MO5</b></td> <td align="char" char="Â±">88.1â€‰Â±â€‰3.43</td> <td align="char" char="Â±">58.6â€‰Â±â€‰3.39</td> <td align="char" char="Â±">34.5â€‰Â±â€‰9.51</td> <td align="char" char="Â±">60.86â€‰Â±â€‰1.07</td> <td align="center">&amp;gt;40</td> <td align="char" char="Â±">1.31â€‰Â±â€‰0.26</td> <td align="char" char="Â±">6.1â€‰Â±â€‰0.0048</td> <td align="center">18.09â€‰Â±â€‰0.38</td> <td align="char" char=".">&amp;gt;30.5</td> </tr> <tr> <td align="left"><b>MO6</b></td> <td align="char" char="Â±">12.3â€‰Â±â€‰1.58</td> <td align="char" char="Â±">64.1â€‰Â±â€‰1.37</td> <td align="char" char="Â±">76.9â€‰Â±â€‰3.54</td> <td align="char" char="Â±">70.96â€‰Â±â€‰0.36</td> <td align="center">8.7â€‰Â±â€‰1.32</td> <td align="char" char="Â±">0.64â€‰Â±â€‰0.04</td> <td align="center">&amp;gt;40</td> <td align="center">&amp;gt;40</td> <td align="char" char=".">13.6</td> </tr> <tr> <td align="left"><b>MO7</b></td> <td align="char" char="Â±">âˆ’16.5â€‰Â±â€‰4.53</td> <td align="char" char="Â±">26.1â€‰Â±â€‰5.44</td> <td align="char" char="Â±">65.3â€‰Â±â€‰1.55</td> <td align="char" char="Â±">70.21â€‰Â±â€‰4.76</td> <td align="center">7.1â€‰Â±â€‰0.41</td> <td align="char" char="Â±">0.25â€‰Â±â€‰0.05</td> <td align="char" char="Â±">20.48â€‰Â±â€‰1.10</td> <td align="center">24.83â€‰Â±â€‰0.34</td> <td align="char" char=".">28.4</td> </tr> <tr> <td align="left"><b>MO8</b></td> <td align="char" char="Â±">83.7â€‰Â±â€‰4.02</td> <td align="char" char="Â±">34.6â€‰Â±â€‰5.44</td> <td align="char" char="Â±">50.6â€‰Â±â€‰3.61</td> <td align="char" char="Â±">74.61â€‰Â±â€‰0.73</td> <td align="center">&amp;gt;40</td> <td align="char" char="Â±">0.32â€‰Â±â€‰0.16</td> <td align="char" char="Â±">12.07â€‰Â±â€‰1.18</td> <td align="center">&amp;gt;40</td> <td align="char" char=".">&amp;gt;125.0</td> </tr> <tr> <td align="left"><b>MO9</b></td> <td align="char" char="Â±">79.8â€‰Â±â€‰1.54</td> <td align="char" char="Â±">51.3â€‰Â±â€‰2.42</td> <td align="char" char="Â±">50.4â€‰Â±â€‰2.42</td> <td align="char" char="Â±">70.21â€‰Â±â€‰5.50</td> <td align="center">&amp;gt;40</td> <td align="char" char="Â±">0.36â€‰Â±â€‰0.16</td> <td align="char" char="Â±">12.01â€‰Â±â€‰2.13</td> <td align="center">&amp;gt;40</td> <td align="char" char=".">&amp;gt;111.1</td> </tr> <tr> <td align="left">Toloxatone</td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="center">1.08â€‰Â±â€‰0.025</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">Â </td> <td align="center">Â </td> <td align="char" char=".">Â </td> </tr> <tr> <td align="left">Lazabemide</td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="center">â€"</td> <td align="char" char="Â±">0.063â€‰Â±â€‰0.015</td> <td align="char" char="Â±">Â </td> <td align="center">Â </td> <td align="char" char=".">Â </td> </tr> <tr> <td align="left">Clorgyline</td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="center">0.007â€‰Â±â€‰0.00070</td> <td align="char" char="Â±">â€"</td> <td align="char" char="Â±">Â </td> <td align="center">Â </td> <td align="char" char=".">Â </td> </tr> <tr> <td align="left">Pargyline</td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">Â </td> <td align="center">â€"</td> <td align="char" char="Â±">0.028â€‰Â±â€‰0.0043</td> <td align="char" char="Â±">Â </td> <td align="center">Â </td> <td align="char" char=".">Â </td> </tr> <tr> <td align="left">Tacrine</td> <td align="char" char="Â±">ã€€</td> <td align="char" char="Â±">ã€€</td> <td align="char" char="Â±">ã€€</td> <td align="char" char="Â±">Â </td> <td align="center">Â </td> <td align="char" char="Â±">Â </td> <td align="char" char="Â±">0.27â€‰Â±â€‰0.019</td> <td align="center">0.060â€‰Â±â€‰0.0022</td> <td align="char" char=".">Â </td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>a</sup></span><p>Values above are the meansâ€‰Â±â€‰SEs of duplicate or triplicate experiments.</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>b</sup></span><p>SIâ€‰=â€‰IC<sub>50</sub> of MAO-A/IC<sub>50</sub> of MAO-B.</p> </div> <div class="fn-type-" title=""> <p>AChE values â€‹were determined after pre-incubation compounds and enzymes for 15â€‰min.</p> </div> </div> </div> <p>Morpholine-containing compounds in this study shared a 1â€"(4-morpholinophenyl) prop-2-en-1-one structure. Introduction of various electron-donating and withdrawing groups onto the <i>para</i> position of the phenyl <b>B</b> ring of the basic chalcone scaffold afforded different derivatives. Surprisingly, unsubstituted <b>MO1</b> inhibited MAO-B more potently than the other eight derivatives. All nine derivatives exhibited MAO-B selectivity. In particular, <b>MO1</b> (IC<sub>50</sub> = 0.030â€‰ÂµM) was âˆ¼2 times more potent than the reversible MAO-B inhibitor lazabemide (IC<sub>50</sub> = 0.063â€‰ÂµM), and had a high selectivity index (SI = &amp;gt;1333.3), which meant that it was the best inhibitor in the series. Regarding MAO-B inhibition, <b>MO1</b> was slightly less potent than the reference irreversible MAO-B inhibitor pargyline (IC<sub>50</sub> = 0.028â€‰ÂµM). The presence of dimethylamino, chloro and bromo substituents at the <i>para</i> position of the chalcone <b>B</b> ring conferred moderate AChE inhibition. Recently, it was reported that shifting of morpholine ring to the phenyl <b>B</b> ring of chalcones showed moderate AChE inhibition<a href="#CIT0035"><sup>35</sup></a>. Results of SAR analysis of MAO-B/AChE inhibitions by the nine compounds are provided in <a href="#F0003">Figure 3</a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 3.</span></a></div>   <p>SAR analysis of MAO-B and AChE inhibitors.</p>   </div> </div> <div class="kineticsofmao-binhibition" title="sec"><span class="label" tagx="label" title="label">2.2.2.</span><div class="title" tagx="title" title="title">
Kinetics of MAO-B inhibition</div> <p>Lineweaverâ€"Burk plots and secondary plots of MAO-B inhibition by <b>MO1</b> showed that <b>MO1</b> is a mixed inhibitor of MAO-B (<i>K<sub>i</sub></i> = 0.018â€‰Â±â€‰0.002) (<a href="#F0004">Figure 4(A,B)</a>). These results suggested that <b>MO1</b> binds to an allosteric site other than the substrate-binding site of MAO-B.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 4.</span></a></div>   <p>Lineweaverâ€"Burk plots of MAO-B inhibition by <b>MO1</b> (A), and respective secondary plots (B) of slopes vs. inhibitor concentrations.</p>   </div> </div> <div class="kineticsofacheinhibitions" title="sec"><span class="label" tagx="label" title="label">2.2.3.</span><div class="title" tagx="title" title="title">
Kinetics of AChE inhibitions</div> <p>Lineweaverâ€"Burk plots and secondary plots showed that <b>MO5</b> and <b>MO9</b> competitively and non-competitively, respectively, inhibited AChE (<a href="#F0005">Figure 5(A,C)</a>) with <i>K<sub>i</sub></i> values of 2.52â€‰Â±â€‰0.17 and 7.04â€‰Â±â€‰0.32â€‰ÂµM, respectively (<a href="#F0005">Figure 5(B,D)</a>), which suggest that <b>MO5</b> is a potent, selective and competitive inhibitor of AChE that binds to the active site of AChE, and that <b>MO9</b> binds to a site other than the active site of AChE and changes the 3D structure of the enzyme, thus inhibiting enzyme activity.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 5.</span></a></div>   <p>Lineweaverâ€"Burk plots of AChE inhibition by <b>MO5</b> (A) and <b>MO9</b> (C), and respective secondary plots (B and D) of slopes vs. inhibitor concentrations.</p>   </div> </div> <div class="analysisofthereversibilitiesofmao-bandacheinhibitions" title="sec"><span class="label" tagx="label" title="label">2.2.4.</span><div class="title" tagx="title" title="title">
Analysis of the reversibilities of MAO-B and AChE inhibitions</div> <p>Inhibition assays were carried out after preincubating MAO-B or AChE with the inhibitors for 15â€‰min. The reversibilities of MAO-B inhibition by <b>MO1</b> and of AChE inhibitions by <b>MO5</b> and <b>MO9</b> were investigated by dialysis<a href="#CIT0034"><sup>34</sup></a>. Dialysis recovered the inhibition of MAO-B by <b>MO1</b> from 21.6% (<i>A</i><sub>U</sub>) to 77.1% (<i>A</i><sub>D</sub>), which was similar to that shown by lazabemide (from 38.8 to 90.0%), a reversible MAO-B inhibitor (<a href="#F0006">Figure 6(A)</a>). On the other hand, inhibition of MAO-B by pargyline (an irreversible inhibitor) was recovered from 10.7 to 16.5%. In addition, inhibitions of AChE by <b>MO5</b> and <b>MO9</b> were recovered by dialysis from 35.8% (A<sub>U</sub>) to 79.2% (A<sub>D</sub>) and from 33.8 to 80.7%, respectively, which were similar to that observed for tacrine (from 32.8 to 91.7%), a reversible AChE inhibitor (<a href="#F0006">Figure 6(B)</a>). These results indicate that <b>MO1</b> is a reversible inhibitor of MAO-B, and that <b>MO5</b> and <b>MO9</b> are reversible inhibitors of AChE.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 6.</span></a></div>   <p>Dialysis recoveries of MAO-B inhibition by <b>MO1</b> (A) and AChE inhibition by <b>MO5</b> and <b>MO9</b> (B). The concentrations of the inhibitors used were approximately 2â€‰Ã—â€‰IC<sub>50</sub> values: <b>MO1</b>, 0.06â€‰ÂµM; <b>MO5</b>, 12.0â€‰ÂµM; <b>MO9</b>, 24.0â€‰ÂµM; lazabemide, 0.12â€‰ÂµM; pargyline, 0.06â€‰ÂµM; and tacrine, 0.54â€‰ÂµM (tacrine was used as a reference reversible inhibitor). For recovery experiments, preincubated enzyme mixtures were dialysed as described in the text.</p>   </div> </div> </div> <div class="bloodâ€" title="sec"><span class="label" tagx="label" title="label">2.3.</span><div class="title" tagx="title" title="title">
Bloodâ€"brain barrier (BBB) permeation</div> <p>The synthesised derivatives were screened for their abilities to cross the BBB using the parallel artificial membrane permeability assay (PAMPA) because this ability is a critical developmental requirement for any drug targeting neurodegenerative disorders or depression. The PAMPA used was validated by comparing the experimentally determined permeabilities of eight commercial drugs with reported values (<a href="#t0002">Table 2</a>). According to reported BBB permeation limits, compounds were classified as follows:<a href="#CIT0036"><sup>36</sup></a> CNS+ (high): Pe (10<sup>âˆ’6â€‰</sup>cm s<sup>âˆ’1</sup>) &amp;gt; 4.00, CNS- (low): Pe (10<sup>âˆ’6â€‰</sup>cm s<sup>âˆ’1</sup>) &amp;lt;2.00 and CNSÂ± (uncertain): Pe (10<sup>âˆ’6â€‰</sup>cm s<sup>âˆ’1</sup>) from 4.00 to 2.00. Our results suggest that all nine synthesised derivatives could cross the BBB, and that <b>MO1</b>, <b>MO5</b> and <b>MO9</b> would be the most effective.</p> <div class="table-wrap_UNKNOWN" id="t0002" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 2.</span> <p>Experimental membrane permeabilities of the synthetic and reference inhibitors.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th align="left">Compounds</th> <th align="center">Bibliography<br /><br />Pe (Ã—10<sup>âˆ’6</sup> cm s<sup>âˆ’1</sup>)</th> <th align="center">Experimental<br /><br />Pe (Ã—10<sup>âˆ’6</sup> cm s<sup>âˆ’1</sup>)</th> <th align="center">Prediction</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left">Testosterone</td> <td align="char" char=".">17.0</td> <td align="char" char="Â±">16.86â€‰Â±â€‰0.67</td> <td align="left">CNS+</td> </tr> <tr> <td align="left">Verapamil</td> <td align="char" char=".">16.0</td> <td align="char" char="Â±">15.69â€‰Â±â€‰0.44</td> <td align="left">CNS+</td> </tr> <tr> <td align="left">Î²-estradiol</td> <td align="char" char=".">12.0</td> <td align="char" char="Â±">11.88â€‰Â±â€‰0.53</td> <td align="left">CNS+</td> </tr> <tr> <td align="left">Progesterone</td> <td align="char" char=".">9.3</td> <td align="char" char="Â±">9.10â€‰Â±â€‰0.11</td> <td align="left">CNS+</td> </tr> <tr> <td align="left">Piroxicam</td> <td align="char" char=".">2.5</td> <td align="char" char="Â±">2.35â€‰Â±â€‰0.30</td> <td align="left">CNS+/-</td> </tr> <tr> <td align="left">Hydrocortisone</td> <td align="char" char=".">1.8</td> <td align="char" char="Â±">1.71â€‰Â±â€‰0.05</td> <td align="left">CNS-</td> </tr> <tr> <td align="left">Lomefloxacin</td> <td align="char" char=".">1.1</td> <td align="char" char="Â±">1.26â€‰Â±â€‰0.01</td> <td align="left">CNS-</td> </tr> <tr> <td align="left">Dopamine</td> <td align="char" char=".">0.2</td> <td align="char" char="Â±">0.21â€‰Â±â€‰0.01</td> <td align="left">CNS-</td> </tr> <tr> <td align="left"><b>MO1</b></td> <td align="center">â€"</td> <td align="char" char="Â±">16.34â€‰Â±â€‰0.16</td> <td align="left">CNS+</td> </tr> <tr> <td align="left"><b>MO5</b></td> <td align="center">â€"</td> <td align="char" char="Â±">14.44â€‰Â±â€‰0.81</td> <td align="left">CNS+</td> </tr> <tr> <td align="left"><b>MO9</b></td> <td align="center">â€"</td> <td align="char" char="Â±">14.61â€‰Â±â€‰0.08</td> <td align="left">CNS+</td> </tr> </tbody> </table> </div> </div> <div class="cytotoxicstudies" title="sec"><span class="label" tagx="label" title="label">2.4.</span><div class="title" tagx="title" title="title">
Cytotoxic studies</div> <p>The biocompatibilities of <b>MO1, MO5</b> and <b>MO9</b> were investigated using an MTT (3â€"(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and normal VERO cells<a href="#CIT0037"><sup>37</sup></a>,<a href="#CIT0038"><sup>38</sup></a>. Results showed that <b>MO1, MO5</b> and <b>MO9</b> were non-toxic to normal VERO cells with IC<sub>50</sub> values of 195.14, 185.44 and 188.34â€‰Âµg/mL, respectively, indicating that the therapeutic potentials of these compounds would be suitable.</p> </div> <div class="totalrossassay" title="sec"><span class="label" tagx="label" title="label">2.5.</span><div class="title" tagx="title" title="title">
Total ROSs assay</div> <p>ROS are considered to be the radicals primarily responsible for the neuronal death observed in various neurodegenerative disorders<a href="#CIT0039"><sup>39</sup></a>. The lead compounds <b>MO1, MO5</b> and <b>MO9</b> were subjected to ROS assays using Hela cells. ROS levels significantly increased in H<sub>2</sub>O<sub>2</sub>-treated Hela cells as determined by fluorescent image analyses (<a href="#F0007">Figure 7(B)</a>). <b>MO1</b> and <b>MO5</b> (<a href="#F0007">Figure 7(C,D)</a>) at 40â€‰Âµg/mL resulted in significantly lower ROS levels than <b>MO9</b> (<a href="#F0007">Figure 7(E)</a>). Interestingly, the colony formation induced by H<sub>2</sub>O<sub>2</sub> was markedly reduced by the lead MAO-B inhibitor <b>MO1</b>, which suggested that the molecule can be highly recommended for the arrest of free radicals in the neurodegenerative disorders.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 7.</span></a></div>   <p>Inhibition of H<sub>2</sub>O<sub>2</sub>-induced ROS generation in human cervical cancer cells. (A) Treatment-naÃ¯ve control cells; (B) Cells treated with 100â€‰Î¼g/mL of H<sub>2</sub>O<sub>2</sub>; (C) Cells treated with 40â€‰Î¼g/mL of <b>MO1</b>; (D) Cells treated with 40â€‰Î¼g/mL of <b>MO5</b>; (E) Cells- treated with 40â€‰Î¼g/mL of <b>MO9</b>.</p>   </div> </div> <div class="computationalstudies" title="sec"><span class="label" tagx="label" title="label">2.6.</span><div class="title" tagx="title" title="title">
Computational studies</div> <p>Initially, <b>MO1</b> and <b>MO5</b> were used as bases for profiling the pharmacological spectra of putative protein targets using the free web platform MuSSel<a href="#CIT0040"><sup>40</sup></a><sup>,</sup><a href="#CIT0041"><sup>41</sup></a>. Interestingly, MAO-B and AChE were predicted to be 13th and 14th targets for <b>MO1</b> and 7th and 15th targets for <b>MO5</b>, respectively. Details are provided in Supporting Information.</p> <p>Docking studies were performed on <b>MO1</b> and <b>MO5</b> using the X-ray resolved structures of MAO-A, MAO-B and AChE in the Protein Data Bank (PDB) as entries 2Z5X, 2VZ5 and 4EY7<a href="#CIT0042"><sup>42â€"45</sup></a>. Docking protocols were performed as we described in a previous study<a href="#CIT0013"><sup>13</sup></a>. Molecular docking simulations were performed to investigate interactions between <b>MO1</b> and <b>MO5</b> and MAO-A, MAO-B and AChE. The docking scores resulting from <i>in silico</i> simulations are reported in <a href="#t0003">Table 3</a>. Results showed that the carbonyl and the 4-morpholin-phenyl groups of the chalcone scaffolds of <b>MO1</b> and <b>MO5</b> hydrogen-bonded with F295 and formed Ï€â€‰âˆ’â€‰Ï€ interactions with the side chain of W286 at the peripheral anionic subsite (PAS) of AChE (<a href="#F0008">Figure 8(A)</a>). Also, the dimethylamino group of <b>MO5</b> established a weak hydrophobic interaction with W86 at the catalytic anionic subsite (CAS). <b>MO1</b> and <b>MO5</b> formed Ï€â€‰âˆ’â€‰Ï€ interactions with the selective MAO-B residue Y326 (<a href="#F0008">Figure 8(B)</a>). In addition, the styryl and dimethylaminophenyl groups of <b>MO1</b> and <b>MO5</b>, respectively, established Ï€â€"Ï€ interactions with Y398 and were sandwiched within an aromatic cage formed by Y328, Y435 and FAD. <b>MO1</b> engaged in a Ï€â€‰âˆ’â€‰Ï€ interaction with Y407 and was entangled in a hydrophobic cage consisting of Y407, Y444 and FAD of MAO-A (<a href="#F0008">Figure 8(C)</a>), whereas <b>MO5</b> established Ï€â€"Ï€ interactions with a selective MAO-A residue F208 using its 4-morpholine-phenyl group. In order to point out the selectivity of <b>MO1</b> and <b>MO5</b>, molecular docking analyses were performed on BChE crystal structure. Docking score values of <b>MO1</b> and <b>MO5</b> for BChE were worse than those for AChE (<a href="#t0003">Table 3</a>). Interestingly, <b>MO1</b> and <b>MO5</b> can predominantly establish hydrophobic interactions in the BChE binding pocket; in particular <b>MO1</b> engaged a Ï€â€"Ï€ interaction with F329, but both compounds cannot make crucial interactions with the catalytic W82 residue (<a href="#F0008">Figure 8(D)</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 8.</span></a></div>   <p>Top scored poses of <b>MO1</b> and <b>MO5</b> for binding with AChE (A), MAO-B (B) and MAO-A (C) are shown on left and right sides, respectively. <b>MO1</b>, <b>MO5</b> and key enzyme residues are displayed as green, yellow and grey sticks, respectively. Green and red arrows indicate Ï€â€"Ï€ interactions and hydrogen bonds, respectively.</p>   </div> <div class="table-wrap_UNKNOWN" id="t0003" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 3.</span> <p>Docking score values for bindings between <b>MO1</b> and <b>MO5</b> and MAO-B or AChE.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup> <colgroup><col width="80pt" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Compounds</th> <th colspan="3" align="center">Docking score (kcal/mol) <hr /> </th> </tr> <tr> <th align="center">AChE</th> <th align="center">MAO-B</th> <th align="center">BChE</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>MO1</b></td> <td align="char" char=".">âˆ’10.31</td> <td align="char" char=".">âˆ’8.67</td> <td align="left">âˆ’7.42</td> </tr> <tr> <td align="left"><b>MO5</b></td> <td align="char" char=".">âˆ’10.12</td> <td align="char" char=".">âˆ’9.34</td> <td align="left">âˆ’6.66</td> </tr> </tbody> </table> </div> <p>Overall, computational analyses provided a sound explanation of the experimental data. Docking scores and the binding modes obtained demonstrated that <b>MO1</b> and <b>MO5</b> can meaningfully interact with MAO-B as indicated by IC<sub>50</sub> experimental values. Interestingly, even if <b>MO1</b> had adopted a similar binding mode in MAO-A and MAO-B binding pockets, the two docking score values would have been quite different, due to a lack of Ï€â€"Ï€ interaction with the MAO-A selective residue F208 and lesser hydrophobic interactions. On the other hand, <b>MO5</b> assumed a switched pose within the MAO-A binding pocket, with its morpholine ring facing FAD, presumably because the dimethylamino substituent on the phenyl ring did not allow adequate access to the binding site. As regards AChE, molecular docking awarded a better score for <b>MO5</b> than <b>MO1</b>, which also agreed with experimental data, despite the resemblance between their binding poses.</p> </div> </div> <div class="conclusion" title="sec"><span class="label" tagx="label" title="label">3.</span><div class="title" tagx="title" title="title">
Conclusion</div> <p>We describe the synthesis of morpholine-containing Î±,Î²-unsaturated ketones, and the results of an investigation of their MAOs and AChE inhibition profiles. Most of the nine compounds synthesised exhibited potent MAO-B inhibition with moderate AChE inhibition. Interestingly, <b>MO1</b> (the lead compound) inhibited MAO-B inhibition in the low nanomolar range and was more potent than lazabemide (the reference compound). The low cytotoxicity and the ability of <b>MO1</b> to transit the BBB support our drug design strategy. In addition, the ROS scavenging efficacy of <b>MO1</b> suggests improved neuroprotective effects.</p> </div> <div class="experimental" title="sec"><span class="label" tagx="label" title="label">4.</span><div class="title" tagx="title" title="title">
Experimental</div> <div class="enzymeassays" title="sec"><span class="label" tagx="label" title="label">4.1.</span><div class="title" tagx="title" title="title">
Enzyme assays</div> <p>MAO-A activity was measured continuously for 20â€‰min at 316â€‰nm using 0.06â€‰mM kynuramine as substrate, as described previously<a href="#CIT0046"><sup>46</sup></a><sup>,</sup><a href="#CIT0047"><sup>47</sup></a>, whereas MAO-B activity was measured for 30â€‰min at 250â€‰nm using 0.3â€‰mM benzylamine as substrate. MAO activity assays were performed using recombinant human MAO-A or MAO-B. A slightly modified version of the method developed by Ellman<a href="#CIT0048"><sup>48</sup></a> was used to measure AChE and BChE activities, using 0.5â€‰mM acetylthiocholine iodide (ATCI) and <i>S</i>-butyrylthiocholine iodide (BTCI), respectively, as substrates for 10â€‰min at 412â€‰nm<a href="#CIT0049"><sup>49</sup></a>. Colour development was performed using 0.5â€‰mM 5,5â€²-dithiobis (2-nitrobenzoic acid) (DTNB), which reacts with thiocholine (a product of ATCI by AChE or of BTCI by BChE) to produce 5-thio 2-nitrobenzoic acid. Preincubation was treated for 15â€‰min before adding ATCI and DTNB.</p> </div> <div class="analysisofenzymeinhibitionsandkinetics" title="sec"><span class="label" tagx="label" title="label">4.2.</span><div class="title" tagx="title" title="title">
Analysis of enzyme inhibitions and kinetics</div> <p>MAO-A, MAO-B, AChE and BChE activities were measured after exposure to inhibitors at a concentration of 10â€‰ÂµM. Inhibitions of MAO-B at 10â€‰ÂµM of these compounds tested were too excessive, and thus, a concentration of 1.0â€‰ÂµM was used. IC<sub>50</sub> values were determined by measuring the residual enzyme activities. Toloxatone, lazabemide and tacrine, were used as reference reversible inhibitors of MAO-A, MAO-B and AChE, respectively, and clorgyline and pargyline as reference irreversible inhibitors of MAO-A and MAO-B, respectively. <i>K<sub>i</sub></i> values and inhibitor types were determined by kinetic testing, as previously described<a href="#CIT0050"><sup>50</sup></a>. Kinetic tests were conducted at 5 different substrate concentrations, and the inhibitor concentrations used were 0, âˆ¼1/2â€‰Ã—â€‰IC<sub>50</sub>, IC<sub>50</sub>, and 2â€‰Ã—â€‰IC<sub>50</sub> values. Lineweaverâ€"Burk plots and their secondary plots were used to determine <i>K<sub>i</sub></i> values and inhibitor types.</p> </div> <div class="analysisofinhibitorreversibilities" title="sec"><span class="label" tagx="label" title="label">4.3.</span><div class="title" tagx="title" title="title">
Analysis of inhibitor reversibilities</div> <p>Inhibition types (reversible or irreversible) were determined by dialysis, as previously described<sup>51,52</sup>, but by using 0.06â€‰mM kynuramine and 0.3â€‰mM benzylamine. For the experiment of AChE, 0.5â€‰mM ATCI was used. Dialysis experiments were performed by preincubating enzymes and inhibitors (or reference inhibitors) at âˆ¼2â€‰Ã—â€‰IC<sub>50</sub> in 0.1â€‰M sodium phosphate buffer (pH 7.2) for 30â€‰min, and then dialysing solutions with stirring for 6â€‰h with a buffer change at 3â€‰h. Residual activities were calculated using the measured activities of undialyzed (A<sub>U</sub>) and dialysed (A<sub>D</sub>) solutions and the activities of untreated controls (i.e. without inhibitor).</p> </div> </div> <div class="supplementary-material" title="supplementary-material"> <div class="title" tagx="title" title="title">
Supplementary Material</div> <div class="local-data" title="local-data">  <div class="title" tagx="title" title="title">
Supplemental Material</div>  <div class="media" title="media"><a href="IENZ_A_1842390_SM5440.pdf">LINK</a> <p>Click here for additional data file.</p>  </div> </div> </div> </div> <div class="back" title="back"> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Disclosure statement</div> <p>No potential conflict of interest was reported by the authors.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CIT0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">RodrÃ­guez-Soacha</span><span class="given-names" tagx="given-names" title="given-names">DA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Scheiner</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Decker</span><span class="given-names" tagx="given-names" title="given-names">M.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">180</span>:<span class="fpage" tagx="fpage" title="fpage">690</span>â€"<span class="lpage" tagx="lpage" title="lpage">706</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31401465">31401465</a></span></span></li> <li tag="ref"><a name="CIT0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhu</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">J.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Multi-target design strategies for the improved treatment of Alzheimer's disease</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">176</span>:<span class="fpage" tagx="fpage" title="fpage">228</span>â€"<span class="lpage" tagx="lpage" title="lpage">47</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31103902">31103902</a></span></span></li> <li tag="ref"><a name="CIT0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Silva</span><span class="given-names" tagx="given-names" title="given-names">MF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dias</span><span class="given-names" tagx="given-names" title="given-names">KST</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gontijo</span><span class="given-names" tagx="given-names" title="given-names">VS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Multi-target directed drugs as a modern approach for drug design towards Alzheimer's disease: an update</span>. <span class="source" tagx="source" title="source">Curr Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">3491</span>â€"<span class="lpage" tagx="lpage" title="lpage">525</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29332563">29332563</a></span></span></li> <li tag="ref"><a name="CIT0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Youdim</span><span class="given-names" tagx="given-names" title="given-names">MBH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Buccafusco</span><span class="given-names" tagx="given-names" title="given-names">JJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders</span>. <span class="source" tagx="source" title="source">Trends Pharmacol Sci</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">26</span>:<span class="fpage" tagx="fpage" title="fpage">27</span>â€"<span class="lpage" tagx="lpage" title="lpage">35</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15629202">15629202</a></span></span></li> <li tag="ref"><a name="CIT0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Carradori</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Silvestri</span><span class="given-names" tagx="given-names" title="given-names">R.</span></span></span><span class="mixed-article-title" title="mixed-article-title">New frontiers in selective human MAO-B inhibitors</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">58</span>:<span class="fpage" tagx="fpage" title="fpage">6717</span>â€"<span class="lpage" tagx="lpage" title="lpage">32</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25915162">25915162</a></span></span></li> <li tag="ref"><a name="CIT0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rehuman</span><span class="given-names" tagx="given-names" title="given-names">NA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jat</span><span class="given-names" tagx="given-names" title="given-names">RK</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A comprehensive review of monoamine oxidase-A inhibitors in their syntheses and potencies</span>. <span class="source" tagx="source" title="source">Comb Chem High Throughput Screen</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">898</span>â€"<span class="lpage" tagx="lpage" title="lpage">914</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32342809">32342809</a></span></span></li> <li tag="ref"><a name="CIT0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parambi</span><span class="given-names" tagx="given-names" title="given-names">DGT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">GE</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases</span>. <span class="source" tagx="source" title="source">Arch Pharm (Weinheim)</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">352</span>:<span class="fpage" tagx="fpage" title="fpage">e1900177</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31478569">31478569</a></span></span></li> <li tag="ref"><a name="CIT0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">HY.</span></span></span><span class="mixed-article-title" title="mixed-article-title">One-compound-multiple-targets strategy to combat Alzheimer's disease</span>. <span class="source" tagx="source" title="source">FEBS Lett</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">579</span>:<span class="fpage" tagx="fpage" title="fpage">5260</span>â€"<span class="lpage" tagx="lpage" title="lpage">4</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16194540">16194540</a></span></span></li> <li tag="ref"><a name="CIT0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Carradori</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ortuso</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Petzer</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">143</span>:<span class="fpage" tagx="fpage" title="fpage">1543</span>â€"<span class="lpage" tagx="lpage" title="lpage">52</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29126727">29126727</a></span></span></li> <li tag="ref"><a name="CIT0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Secci</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Carradori</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Petzer</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: synthesis, biological activity and computational analysis</span>. <span class="source" tagx="source" title="source">J Enzyme Inhib Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">34</span>:<span class="fpage" tagx="fpage" title="fpage">597</span>â€"<span class="lpage" tagx="lpage" title="lpage">612</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30727777">30727777</a></span></span></li> <li tag="ref"><a name="CIT0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tzara</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xanthopoulos</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kourounakis</span><span class="given-names" tagx="given-names" title="given-names">AP.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Morpholine as a scaffold in medicinal chemistry: An update on synthetic strategies</span>. <span class="source" tagx="source" title="source">ChemMedChem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">15</span>:<span class="fpage" tagx="fpage" title="fpage">392</span>â€"<span class="lpage" tagx="lpage" title="lpage">403</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32017384">32017384</a></span></span></li> <li tag="ref"><a name="CIT0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kourounakis</span><span class="given-names" tagx="given-names" title="given-names">AP</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xanthopoulos</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tzara</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules</span>. <span class="source" tagx="source" title="source">Med Res Rev</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">40</span>:<span class="fpage" tagx="fpage" title="fpage">709</span>â€"<span class="lpage" tagx="lpage" title="lpage">52</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31512284">31512284</a></span></span></li> <li tag="ref"><a name="CIT0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reeta</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baek</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">JP</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rangarajan</span><span class="given-names" tagx="given-names" title="given-names">TM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Ethyl acetohydroxamate incorporated chalcones: Unveiling a novel class of chalcones for multitarget monoamine oxidase-B inhibitors against Alzheimerâ€™s disease</span>. <span class="source" tagx="source" title="source">CNS Neurol Disord Drug Targets</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">18</span>:<span class="fpage" tagx="fpage" title="fpage">643</span>â€"<span class="lpage" tagx="lpage" title="lpage">54</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31550216">31550216</a></span></span></li> <li tag="ref"><a name="CIT0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guglielmi</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Secci</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Carradori</span><span class="given-names" tagx="given-names" title="given-names">S.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Chalcones: unearthing their therapeutic possibility as monoamine oxidase B inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">205</span>:<span class="fpage" tagx="fpage" title="fpage">112650</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32920430">32920430</a></span></span></li> <li tag="ref"><a name="CIT0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parambi</span><span class="given-names" tagx="given-names" title="given-names">DGT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sivasankarapillai</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Uddin</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Perspective design of chalcones for the management of CNS disorders: a mini-review</span>. <span class="source" tagx="source" title="source">CNS Neurol Disord Drug Targets</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">18</span>:<span class="fpage" tagx="fpage" title="fpage">432</span>â€"<span class="lpage" tagx="lpage" title="lpage">45</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31187716">31187716</a></span></span></li> <li tag="ref"><a name="CIT0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhuang</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sheng</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Chalcone: a privileged structure in medicinal chemistry</span>. <span class="source" tagx="source" title="source">Chem Rev</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">117</span>:<span class="fpage" tagx="fpage" title="fpage">7762</span>â€"<span class="lpage" tagx="lpage" title="lpage">810</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28488435">28488435</a></span></span></li> <li tag="ref"><a name="CIT0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Haridas</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Suresh</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Monoamine oxidase inhibitory action of chalcones: a mini review</span>. <span class="source" tagx="source" title="source">Cent Nerv Syst Agents Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">16</span>:<span class="fpage" tagx="fpage" title="fpage">120</span>â€"<span class="lpage" tagx="lpage" title="lpage">36</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26429556">26429556</a></span></span></li> <li tag="ref"><a name="CIT0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chimenti</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fioravanti</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bolasco</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Chalcones: a valid scaffold for monoamine oxidases inhibitors</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">52</span>:<span class="fpage" tagx="fpage" title="fpage">2818</span>â€"<span class="lpage" tagx="lpage" title="lpage">24</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19378991">19378991</a></span></span></li> <li tag="ref"><a name="CIT0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">GE</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">UÃ§ar</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: synthesis, biochemistry and molecular docking studies</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2015</span>; <span class="volume" tagx="volume" title="volume">62</span>:<span class="fpage" tagx="fpage" title="fpage">22</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26189013">26189013</a></span></span></li> <li tag="ref"><a name="CIT0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">UÃ§ar</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">GE</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Monoamine oxidase inhibitory activity: methyl-versus chlorochalcone derivatives</span>. <span class="source" tagx="source" title="source">Chem Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">11</span>:<span class="fpage" tagx="fpage" title="fpage">2649</span>â€"<span class="lpage" tagx="lpage" title="lpage">55</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27902880">27902880</a></span></span></li> <li tag="ref"><a name="CIT0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Haridas</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">UÃ§ar</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis, biochemistry, and computational studies of brominated thienyl chalcones: a new class of reversible MAO-B inhibitors</span>. <span class="source" tagx="source" title="source">Chem Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">11</span>:<span class="fpage" tagx="fpage" title="fpage">1161</span>â€"<span class="lpage" tagx="lpage" title="lpage">71</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27159243">27159243</a></span></span></li> <li tag="ref"><a name="CIT0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hammuda</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shalaby</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rovida</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">114</span>:<span class="fpage" tagx="fpage" title="fpage">162</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26974383">26974383</a></span></span></li> <li tag="ref"><a name="CIT0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parambi</span><span class="given-names" tagx="given-names" title="given-names">DGT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Oh</span><span class="given-names" tagx="given-names" title="given-names">JM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baek</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and biological evaluation of oxygenated chalcones as potent and selective MAO-B inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">93</span>:<span class="fpage" tagx="fpage" title="fpage">103335</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31606547">31606547</a></span></span></li> <li tag="ref"><a name="CIT0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lakshminarayan</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baek</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kannappan</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Ethoxylated head of chalcones as a new class of multi-targeted MAO inhibitors</span>. <span class="source" tagx="source" title="source">Chem Select</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">4</span>:<span class="fpage" tagx="fpage" title="fpage">6614</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.</span></li> <li tag="ref"><a name="CIT0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Shalaby</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Petzer</span><span class="given-names" tagx="given-names" title="given-names">JP</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Petzer</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs</span>. <span class="source" tagx="source" title="source">J Enzyme Inhib Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">34</span>:<span class="fpage" tagx="fpage" title="fpage">863</span>â€"<span class="lpage" tagx="lpage" title="lpage">76</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30915862">30915862</a></span></span></li> <li tag="ref"><a name="CIT0026" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kong</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sun</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jiang</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hu</span><span class="given-names" tagx="given-names" title="given-names">Y.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, and evaluation of 1, 4-benzodioxan-substituted chalcones as selective and reversible inhibitors of human monoamine oxidase B</span>. <span class="source" tagx="source" title="source">J Enzyme Inhib Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">35</span>:<span class="fpage" tagx="fpage" title="fpage">1513</span>â€"<span class="lpage" tagx="lpage" title="lpage">25</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32705910">32705910</a></span></span></li> <li tag="ref"><a name="CIT0027" /><span class="label" tagx="label" title="label">27</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Oh</span><span class="given-names" tagx="given-names" title="given-names">JM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rangarajan</span><span class="given-names" tagx="given-names" title="given-names">TM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reeta</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel class of chalcone oxime ethers as potent monoamine oxidase-B and acetylcholinesterase inhibitors</span>. <span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">20</span>:<span class="fpage" tagx="fpage" title="fpage">2536</span>.</span></li> <li tag="ref"><a name="CIT0028" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tian</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">360</span>â€"<span class="lpage" tagx="lpage" title="lpage">71</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27856236">27856236</a></span></span></li> <li tag="ref"><a name="CIT0029" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xiao</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Qiang</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">1030</span>â€"<span class="lpage" tagx="lpage" title="lpage">41</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28011206">28011206</a></span></span></li> <li tag="ref"><a name="CIT0030" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">26</span>:<span class="fpage" tagx="fpage" title="fpage">1102</span>â€"<span class="lpage" tagx="lpage" title="lpage">15</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29409707">29409707</a></span></span></li> <li tag="ref"><a name="CIT0031" /><span class="label" tagx="label" title="label">31</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tian</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Qiang</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Song</span><span class="given-names" tagx="given-names" title="given-names">Q</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Flurbiprofen-chalcone hybrid mannich base derivatives as balanced multifunctional agents against Alzheimerâ€™s disease: design, synthesis and biological evaluation</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">94</span>:<span class="fpage" tagx="fpage" title="fpage">103447</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31810756">31810756</a></span></span></li> <li tag="ref"><a name="CIT0032" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Privileged pharmacophore of FDA approved drugs in combination with chalcone framework: a new hope for Alzheimer's treatment</span>. <span class="source" tagx="source" title="source">Comb Chem High Throughput Screen</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">842</span>â€"<span class="lpage" tagx="lpage" title="lpage">846</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32723232">32723232</a></span></span></li> <li tag="ref"><a name="CIT0033" /><span class="label" tagx="label" title="label">33</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baek</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parambi</span><span class="given-names" tagx="given-names" title="given-names">DGT</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: fluorinated chalcones of morpholine versus imidazole</span>. <span class="source" tagx="source" title="source">Arch Pharm</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">352</span>:<span class="fpage" tagx="fpage" title="fpage">e1800309</span>.</span></li> <li tag="ref"><a name="CIT0034" /><span class="label" tagx="label" title="label">34</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Maliyakkal</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eom</span><span class="given-names" tagx="given-names" title="given-names">BH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Heo</span><span class="given-names" tagx="given-names" title="given-names">JH</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A new potent and selective monoamine oxidase-B inhibitor with extended conjugation in a chalcone framework: 1-[4-(morpholin-4-yl)â€Œphenyl]-5-phenylpenta-2,4-dien-1-one</span>. <span class="source" tagx="source" title="source">ChemMedChem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">15</span>:<span class="fpage" tagx="fpage" title="fpage">1629</span>â€"<span class="lpage" tagx="lpage" title="lpage">33</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32583952">32583952</a></span></span></li> <li tag="ref"><a name="CIT0035" /><span class="label" tagx="label" title="label">35</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Polo</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nicol Ibarra-Arellano</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Prent-Penalozaa</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Ultrasound-assisted synthesis of novel chalcone, heterochalcone and bis-chalcone derivatives and the evaluation of their antioxidant properties and as acetylcholinesterase inhibitors</span> . <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">90</span>:<span class="fpage" tagx="fpage" title="fpage">103034</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31280015">31280015</a></span></span></li> <li tag="ref"><a name="CIT0036" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Di</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kerns</span><span class="given-names" tagx="given-names" title="given-names">EH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fan</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">High throughput artificial membrane permeability assay for blood-brain barrier</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">38</span>:<span class="fpage" tagx="fpage" title="fpage">223</span>â€"<span class="lpage" tagx="lpage" title="lpage">32</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12667689">12667689</a></span></span></li> <li tag="ref"><a name="CIT0037" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Suresh</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baek</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ramakrishnan</span><span class="given-names" tagx="given-names" title="given-names">SP</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Discovery of potent and reversible MAO-B inhibitors as furanochalcones</span>. <span class="source" tagx="source" title="source">Int J Biol Macromol</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">108</span>:<span class="fpage" tagx="fpage" title="fpage">660</span>â€"<span class="lpage" tagx="lpage" title="lpage">4</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29195801">29195801</a></span></span></li> <li tag="ref"><a name="CIT0038" /><span class="label" tagx="label" title="label">38</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dev</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Parambi</span><span class="given-names" tagx="given-names" title="given-names">DGT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baby</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">An environment-friendly synthesis of piperonal chalcones and their cytotoxic and antioxidant evaluation</span>. <span class="source" tagx="source" title="source">Lett Drug Des Drug Discov</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">17</span>:<span class="fpage" tagx="fpage" title="fpage">138</span>â€"<span class="lpage" tagx="lpage" title="lpage">44</span>.</span></li> <li tag="ref"><a name="CIT0039" /><span class="label" tagx="label" title="label">39</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cha</span><span class="given-names" tagx="given-names" title="given-names">HJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hong</span><span class="given-names" tagx="given-names" title="given-names">SH</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Protective effects of phloroglucinol on oxidative stressâ€"induced DNA damage and apoptosis through activation of the Nrf2/HO-1 signaling pathway in HaCaT human keratinocytes</span>. <span class="source" tagx="source" title="source">Mar Drugs</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">17</span>:<span class="fpage" tagx="fpage" title="fpage">225</span>.</span></li> <li tag="ref"><a name="CIT0040" /><span class="label" tagx="label" title="label">40</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Montaruli</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alberga</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ciriaco</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Accelerating drug discovery by early protein drug target prediction based on multi-fingerprint similarity search</span>. <span class="source" tagx="source" title="source">Molecules</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">24</span>:<span class="fpage" tagx="fpage" title="fpage">2233</span>.</span></li> <li tag="ref"><a name="CIT0041" /><span class="label" tagx="label" title="label">41</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alberga</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Trisciuzzi</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Montaruli</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">A new approach for drug target and bioactivity prediction: the multifingerprint similarity search algorithm (MuSSeL)</span>. <span class="source" tagx="source" title="source">J Chem Inf Model</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">59</span>:<span class="fpage" tagx="fpage" title="fpage">586</span>â€"<span class="lpage" tagx="lpage" title="lpage">96</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30485097">30485097</a></span></span></li> <li tag="ref"><a name="CIT0042" /><span class="label" tagx="label" title="label">42</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Son</span><span class="given-names" tagx="given-names" title="given-names">SY</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ma</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kondou</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors</span>. <span class="source" tagx="source" title="source">Proc Natl Acad Sci USA</span><span class="year" tagx="year" title="year">2008</span>;<span class="volume" tagx="volume" title="volume">105</span>:<span class="fpage" tagx="fpage" title="fpage">5739</span>â€"<span class="lpage" tagx="lpage" title="lpage">44</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18391214">18391214</a></span></span></li> <li tag="ref"><a name="CIT0043" /><span class="label" tagx="label" title="label">43</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Binda</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pisani</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">50</span>:<span class="fpage" tagx="fpage" title="fpage">5848</span>â€"<span class="lpage" tagx="lpage" title="lpage">52</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17915852">17915852</a></span></span></li> <li tag="ref"><a name="CIT0044" /><span class="label" tagx="label" title="label">44</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cheung</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rudolph</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Burshteyn</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Structures of human acetylcholinesterase in complex with pharmacologically important ligands</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">55</span>:<span class="fpage" tagx="fpage" title="fpage">10282</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23035744">23035744</a></span></span></li> <li tag="ref"><a name="CIT0045" /><span class="label" tagx="label" title="label">45</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">KoÅ¡ak</span><span class="given-names" tagx="given-names" title="given-names">U</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brus</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Knez</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Development of an in-vivo active reversible butyrylcholinesterase inhibitor</span>. <span class="source" tagx="source" title="source">Sci Rep</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">6</span>:<span class="fpage" tagx="fpage" title="fpage">39495</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28000737">28000737</a></span></span></li> <li tag="ref"><a name="CIT0046" /><span class="label" tagx="label" title="label">46</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mathew</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baek</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Grace Thomas Parambi</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors</span>. <span class="source" tagx="source" title="source">MedChemComm</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">9</span>:<span class="fpage" tagx="fpage" title="fpage">1871</span>â€"<span class="lpage" tagx="lpage" title="lpage">81</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30568755">30568755</a></span></span></li> <li tag="ref"><a name="CIT0047" /><span class="label" tagx="label" title="label">47</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baek</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ryu</span><span class="given-names" tagx="given-names" title="given-names">HW</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Rhamnocitrin isolated from <i>Prunus padus</i> var. seoulensis: a potent and selective reversible inhibitor of human monoamine oxidase A</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">28</span>:<span class="fpage" tagx="fpage" title="fpage">317</span>â€"<span class="lpage" tagx="lpage" title="lpage">25</span>.</span></li> <li tag="ref"><a name="CIT0048" /><span class="label" tagx="label" title="label">48</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ellman</span><span class="given-names" tagx="given-names" title="given-names">GL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Courtney</span><span class="given-names" tagx="given-names" title="given-names">KD</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Andres</span><span class="given-names" tagx="given-names" title="given-names">V</span><span class="suffix" tagx="suffix" title="suffix">Jr</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Feather-Stone</span><span class="given-names" tagx="given-names" title="given-names">RM.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A new and rapid colorimetric determination of acetylcholinesterase activity</span>. <span class="source" tagx="source" title="source">Biochem Pharmacol</span><span class="year" tagx="year" title="year">1961</span>;<span class="volume" tagx="volume" title="volume">7</span>:<span class="fpage" tagx="fpage" title="fpage">88</span>â€"<span class="lpage" tagx="lpage" title="lpage">95</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/13726518">13726518</a></span></span></li> <li tag="ref"><a name="CIT0049" /><span class="label" tagx="label" title="label">49</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">JP</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kang</span><span class="given-names" tagx="given-names" title="given-names">MG</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">JY</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Potent inhibition of acetylcholinesterase by sargachromanol I from <i>Sargassum</i> siliquastrum and by selected natural compounds</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">89</span>:<span class="fpage" tagx="fpage" title="fpage">103043</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31200287">31200287</a></span></span></li> <li tag="ref"><a name="CIT0050" /><span class="label" tagx="label" title="label">50</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">HW</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ryu</span><span class="given-names" tagx="given-names" title="given-names">HW</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kang</span><span class="given-names" tagx="given-names" title="given-names">MG</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of <i>Sophora flavescens</i></span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">26</span>:<span class="fpage" tagx="fpage" title="fpage">4714</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27575476">27575476</a></span></span></li> <li tag="ref"><a name="CIT0051" /><span class="label" tagx="label" title="label">51</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baek</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">HW</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ryu</span><span class="given-names" tagx="given-names" title="given-names">HW</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Selective inhibition of monoamine oxidase A by hispidol</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">15</span>:<span class="fpage" tagx="fpage" title="fpage">58</span>â€"<span class="lpage" tagx="lpage" title="lpage">588</span>.</span></li> <li tag="ref"><a name="CIT0052" /><span class="label" tagx="label" title="label">52</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sasidharan</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baek</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Manju</span><span class="given-names" tagx="given-names" title="given-names">SL</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Imidazole bearing chalcones as a new class of monoamine oxidase inhibitors</span>. <span class="source" tagx="source" title="source">Biomed Pharmacother</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">106</span>:<span class="fpage" tagx="fpage" title="fpage">8</span>â€"<span class="lpage" tagx="lpage" title="lpage">13</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29940538">29940538</a></span></span></li> </ul> </div> </div>  </body></html>